Initiating Pancreatic Neuroendocrine Tumor (pNET) Screening in Young MEN1 Patients
| Autor: | Olaf M. Dekkers, Gerlof D. Valk, Wouter T Zandee, M. R. Vriens, Wouter W. de Herder, Bas Havekes, Mirthe J Klein Haneveld, Annenienke C van de Ven, Peter H. Bisschop, Carolina R.C. Pieterman, Madeleine L. Drent, Annemarie A Verrijn Stuart, Mark J C van Treijen, Rachel S van Leeuwaarde |
|---|---|
| Přispěvatelé: | Internal Medicine, Internal medicine, Amsterdam Neuroscience - Mood, Anxiety, Psychosis, Stress & Sleep, Amsterdam Gastroenterology Endocrinology Metabolism, Interne Geneeskunde, MUMC+: MA Endocrinologie (9), RS: NUTRIM - R1 - Obesity, diabetes and cardiovascular health, Endocrinology, AMS - Ageing & Vitality, AMS - Musculoskeletal Health |
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
Oncology
Male Databases Factual Endocrinology Diabetes and Metabolism Neuroendocrine Tumors/diagnosis Clinical Biochemistry Disease Biochemistry multiple endocrine neoplasia type 1 Endocrinology Medicine Age of Onset Multiple endocrine neoplasia Child Early Detection of Cancer Netherlands ENDOCRINE NEOPLASIA TYPE-1 education.field_of_study INTERVAL-CENSORED-DATA Middle Aged Prognosis Penetrance age-related penetrance Tumor Burden Survival Rate Neuroendocrine Tumors Child Preschool Cohort surveillance Female Rare cancers Radboud Institute for Health Sciences [Radboudumc 9] Adult Diagnostic Imaging medicine.medical_specialty pancreatic NET Adolescent Population Context (language use) Netherlands/epidemiology Databases Young Adult SDG 3 - Good Health and Well-being Internal medicine Humans MEN1 Pancreatic Neoplasms/diagnosis education Preschool Survival analysis Factual Aged Retrospective Studies business.industry Biochemistry (medical) medicine.disease Pancreatic Neoplasms Multiple Endocrine Neoplasia Type 1/physiopathology Early Detection of Cancer/methods business Follow-Up Studies |
| Zdroj: | Journal of Clinical Endocrinology and Metabolism, 106, 3515-3525 Journal of Clinical Endocrinology and Metabolism, 106(12), 3515-3525. Endocrine Society Journal of Clinical Endocrinology and Metabolism, 106(12), 3515-3525. ENDOCRINE SOC Journal of Clinical Endocrinology and Metabolism, 106(12), 3515-3525. The Endocrine Society Journal of Clinical Endocrinology & Metabolism, 106(12), 3515-3525. Oxford University Press Journal of Clinical Endocrinology and Metabolism, 106, 12, pp. 3515-3525 Journal of clinical endocrinology and metabolism, 106(12), 3515-3525. The Endocrine Society Klein Haneveld, M J, van Treijen, M J C, Pieterman, C R C, Dekkers, O M, van de Ven, A, de Herder, W W, Zandee, W T, Drent, M L, Bisschop, P H, Havekes, B, Vriens, M R, Verrijn Stuart, A A, Valk, G D & van Leeuwaarde, R S 2021, ' Initiating Pancreatic Neuroendocrine Tumor (pNET) Screening in Young MEN1 Patients : Results from the DutchMEN Study Group ', Journal of Clinical Endocrinology and Metabolism, vol. 106, no. 12, pp. 3515-3525 . https://doi.org/10.1210/clinem/dgab569 |
| ISSN: | 0021-972X |
| DOI: | 10.1210/clinem/dgab569 |
| Popis: | ContextNonfunctioning pancreatic neuroendocrine tumors (NF-pNETs) are highly prevalent and constitute an important cause of mortality in patients with multiple endocrine neoplasia type 1 (MEN1). Still, the optimal age to initiate screening for pNETs is under debate.ObjectiveThe aim of this work is to assess the age of occurrence of clinically relevant NF-pNETs in young MEN1 patients.MethodsPancreatic imaging data of MEN1 patients were retrieved from the DutchMEN Study Group database. Interval-censored survival methods were used to describe age-related penetrance, compare survival curves, and develop a parametric model for estimating the risk of having clinically relevant NF-pNET at various ages. The primary objective was to assess age at occurrence of clinically relevant NF-pNET (size ≥ 20 mm or rapid growth); secondary objectives were the age at occurrence of NF-pNET of any size and pNET-associated metastasized disease.ResultsFive of 350 patients developed clinically relevant NF-pNETs before age 18 years, 2 of whom subsequently developed lymph node metastases. No differences in clinically relevant NF-pNET–free survival were found for sex, time frame, and type of MEN1 diagnosis or genotype. The estimated ages (median, 95% CI) at a 1%, 2.5%, and 5% risk of having developed a clinically relevant tumor are 9.5 (6.5-12.7), 13.5 (10.2-16.9), and 17.8 years (14.3-21.4), respectively.ConclusionAnalyses from this population-based cohort indicate that start of surveillance for NF-pNETs with pancreatic imaging at age 13 to 14 years is justified. The psychological and medical burden of screening at a young age should be considered. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|